For this study, VirtualScopics will analyze magnetic resonance imaging (MRI) data on subjects with osteoarthritis, and will be responsible for co-managing the collection of MRI data from sites located throughout North America, Asia and Europe.
According to the company, VirtualScopics is able to integrate in-depth knowledge of image-based biomarkers, expertise in a variety of medical imaging techniques, and proprietary software tools that can precisely assess disease progression after the intervention of a drug or device, with fewer patients and at a lower cost than conventional approaches.
“GlaxoSmithKline is a global leader in drug development, consistently ranking as one of the world’s top five spenders in ethical R&D,” said Bob Klimasewski, president and CEO of VirtualScopics. “Their decision to collaborate with VirtualScopics on a study of this magnitude demonstrates the value placed on our technology and capabilities.”